Keyphrases
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
100%
Gefitinib
44%
Erlotinib
44%
Hepatocyte Growth Factor
22%
PC-9 Cell
22%
Affect Sensitivity
22%
Lung Cancer
11%
Resistant Cells
11%
Surrogate Marker
11%
Pyrosequencing
11%
Anticancer Effect
11%
Cancer Cell Proliferation
11%
EGFR Inhibitors
11%
Drug Resistance
11%
Migratory Ability
11%
Repeated Treatment
11%
Cross-resistance
11%
MET Amplification
11%
Migration Ability
11%
Cellular Sensitivity
11%
EGFR T790M mutation
11%
Enhanced Migration
11%
Invasive Ability
11%
Gene Amplification
11%
Resistance to EGFR-TKIs
11%
Invasion Ability
11%
MET Gene Amplification
11%
Cellular Effects
11%
Resistance Development
11%
Passage number
11%
Pharmacology, Toxicology and Pharmaceutical Science
Epidermal Growth Factor Receptor
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Gefitinib
40%
Erlotinib
40%
Scatter Factor
20%
Malignant Neoplasm
10%
Disease Marker
10%
Lung Cancer
10%
Drug Resistance
10%
Cross-Resistance
10%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Receptor Tyrosine Kinase Inhibitors
100%
Gefitinib
33%
Erlotinib
33%
Hepatocyte Growth Factor
16%
Gene Amplification
16%
Cell Proliferation
8%
Cancer Cell
8%
Anticancer
8%
Drug Resistance
8%
Cross Resistance
8%
Pyrosequencing
8%